Genprex publishes data from Acclaim-1 Phase 1 trial of Reqorsa Gene Therapy

Genprex (GNPX) announced the publication of data from its Acclaim-1 Phase 1 clinical trial of Reqorsa Gene Therapy in combination with Tagrisso in patients with advanced non-small cell lung cancer, NSCLC, in the peer-reviewed journal Clinical Lung Cancer. The reported results showed no Dose Limiting Toxicities, DLTs, established a Recommended Phase 2 Dose, RP2D, of 0.12 mg/kg and provided data showing early efficacy of REQORSA in combination with osimertinib. Of the 12 patients treated with escalating doses of REQORSA and standard doses of osimertinib, all of whom had progressed on osimertinib containing regimens, three patients had experienced prolonged time to progression, including one with continuing partial response.